Natera (NASDAQ:NTRA) Downgraded by StockNews.com

Natera (NASDAQ:NTRA) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Friday.

NTRA has been the topic of several other reports. The Goldman Sachs Group boosted their target price on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Canaccord Genuity Group upped their price objective on Natera from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, August 27th. Leerink Partners raised their target price on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Piper Sandler restated an “overweight” rating and issued a $150.00 target price on shares of Natera in a research report on Friday, September 13th. Finally, Morgan Stanley increased their price target on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $124.44.

Natera Price Performance

NTRA stock opened at $117.67 on Friday. Natera has a 1 year low of $36.90 and a 1 year high of $133.54. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The firm has a market capitalization of $14.55 billion, a PE ratio of -48.03 and a beta of 1.53. The business has a 50 day simple moving average of $123.24 and a 200-day simple moving average of $111.34.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. During the same period in the prior year, the business earned ($0.97) EPS. The firm’s quarterly revenue was up 58.1% on a year-over-year basis. Equities research analysts anticipate that Natera will post -1.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Michael Burkes Brophy sold 691 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $118.81, for a total value of $82,097.71. Following the sale, the chief financial officer now directly owns 72,709 shares in the company, valued at approximately $8,638,556.29. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Natera news, CFO Michael Burkes Brophy sold 691 shares of the company’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $118.81, for a total transaction of $82,097.71. Following the sale, the chief financial officer now owns 72,709 shares in the company, valued at $8,638,556.29. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Daniel Rabinowitz sold 1,057 shares of Natera stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $102.77, for a total value of $108,627.89. Following the completion of the transaction, the insider now owns 206,400 shares of the company’s stock, valued at $21,211,728. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,149 shares of company stock worth $6,007,018 over the last 90 days. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Natera

A number of large investors have recently modified their holdings of the company. Itau Unibanco Holding S.A. purchased a new stake in shares of Natera during the 2nd quarter worth $28,000. Quarry LP lifted its holdings in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after buying an additional 190 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares in the last quarter. Tobam purchased a new position in shares of Natera in the 2nd quarter valued at about $74,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of Natera during the 1st quarter worth about $83,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.